AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02617940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fissure sealant
Description: Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil).
Study NCT02617940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral hygiene orientation
Description: Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
Study NCT03067285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELV/COBI/FTC/TAF
Description: Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
Study NCT03067285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG/3TC/ABC + ELV/COBI/FTC/TAF
Description: Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
Study NCT01036529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spinal Cord Stimulator
Description: Programming settings will be specific to the individual needs in accordance with the labeling
Study NCT01036529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Back Surgery
Description: Different types of back surgery may be performed
Study NCT03302455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eCBTI
Description: The brief eCBTI contains a one-week core course: sleep hygiene education, sleep restriction, stimulus control, relaxation audios, cognitive components, information about sleeping pills, and a brief overview. In addition, individual customized sleep restriction and stimulation control treatments were provided according to the subject's previous 2-week sleep status.
Study NCT05782192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAL067
Description: SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)
Study NCT05782192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin
Description: Alogliptin 25mg(1 tablet) and placebo 6mg (2 tablet)
Study NCT05782192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 6mg (2 tablet) and placebo 25mg (1 tablet)
Study NCT02614482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Administer medication to patients with overactive bladder
Study NCT03696082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Activity
Description: Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
Study NCT03696082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
Study NCT03696082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
Study NCT03696082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
Study NCT03910166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drug-coated balloon catheter（Orchid, Acotec）
Description: After predilation, using drug-coated balloon catheter to cover the whole treated segment
Study NCT03910166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracranial artery stent system（APOLLO）
Description: stent assisted angioplasty
Study NCT00755547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
Study NCT02333981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: passive oral motor therapy for drooling
Description: 7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
Study NCT00469963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: quality-of-life assessment
Study NCT00469963 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 resin microspheres
Description: radiation therapy
Study NCT02681120 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Study NCT02681120 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Study NCT02321891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroConn DC Stimulator Plus, tDCS
Description: transcranial electrical stimulation intervention with two experimental protocols
Study NCT02189408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Study NCT01193166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: 78, 117, 156, or 234 mg monthly injection for 12 months
Study NCT01193166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: flexible dosing as prescribed by the study doctor for 12 months
Study NCT01193166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: flexible dosing as prescribed by the study doctor for 12 months
Study NCT01193166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: flexible dosing as prescribed by the study doctor for 12 months
Study NCT01193166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidole
Description: flexible dosing as prescribed by the study doctor for 12 months
Study NCT01193166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine
Description: flexible dosing as prescribed by the study doctor for 12 months
Study NCT01193166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perphenazine
Description: flexible dosing as prescribed by the study doctor for 12 months
Study NCT01193166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paliperidone
Description: flexible dosing as prescribed by the study doctor for 12 months
Study NCT03785587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofpironium Bromide Gel, 15%
Description: Sofpironium Bromide Gel, 15%
Study NCT01289106 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepavax-Gene
Description: 20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
Study NCT01289106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepavax-Gene
Description: 20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
Study NCT01289106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepavax-Gene
Description: 40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
Study NCT01504581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM10660A
Description: Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg
Study NCT01504581 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HM10660A placebo
Description: Single dose of HM10660A Placebo
Study NCT01504581 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: Single dose of Pegasys 180ug
Study NCT03333395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized heparin and salbutamol
Description: HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
Study NCT03333395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized salbutamol
Description: S Group medications (control group) (30 patients) which was prepared by adding Salbutamol 5mg/2.5ml Nebulizer Solution + Na cl 0.9% 5ml.
Study NCT01532544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilomedin and Integrilin
Description: Continuous infusion
Study NCT01532544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: low molecular weight heparin.
Study NCT05189249 — intervention group
Intervention type: OTHER
Intervention: No intervention performed
Description: No intervention performed. Participants were enrolled retrospectively and medical records were accessed for data.
Study NCT02907853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: as described above
Study NCT01299571 — intervention group
Intervention type: DRUG
Intervention: Dutasteride
Description: Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study NCT04147975 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RaPID/BSI Test
Description: RaPID/BSI Test
Study NCT01390324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of naratriptan+naproxen
Description: Tablets containing naratriptan 2,5 mg + naproxen 500 mg
Study NCT01390324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naratriptan
Description: Tablets containing naratriptan 2,5 mg
Study NCT01390324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Tablets containing naproxen 500 mg
Study NCT02681120 — intervention group
Intervention type: PROCEDURE
Intervention: Mammogram
Study NCT04169776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve (taVNS) stimulation
Description: Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.
Study NCT04726657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed Human Isophane Insulin Suspension + Human Insulin Injection
Description: premixed human insulin
Study NCT04726657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed Insulin
Description: Premixed Insulin Analog Biphasic Aspart 30
Study NCT03236168 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ivermectin
Description: A single weight based dose of ivermectin
Study NCT03236168 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Permethrin 5%
Description: Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
Study NCT03236168 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Malathion Shampoo 0.5%
Description: Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
Study NCT01522144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Decision support
Description: Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
Study NCT01826266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PER977, Placebo
Study NCT00893100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: 2%,3 times daily
Study NCT02387606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo once daily.
Study NCT05327231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 every 21 days a cycle.
Study NCT00995774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic therapy
Description: 12 sessions of robot therapy for arm and hand function
Study NCT02387606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
Study NCT03772132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mutation and signal pathway activation status analysis Drug: FORFIRINOX
Description: Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy
Study NCT03066921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic packet
Description: Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
Study NCT03066921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
Study NCT05213182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Women of Today
Description: Adolescent mothers engaged in the development and implementation of the intervention which also involved key community stakeholders to address stigma related to mental illness and adolescent motherhood. Community health workers and peer educators in the intervention arm were recruited and trained on co-facilitating peer support groups. The intervention arm (n=104 adolescent mothers) participated in the peer support groups and completed sociodemographic, base-, mid-, and end-line surveys. The control arm (n=79 adolescent mothers) completed sociodemographic, base-, mid- and end-line surveys. Peer support groups (12 groups with 6-12 participants in each group) met in-person twice a month and completed 12 peer-group sessions from May-August 2019 addressing participant identified topics such as depression. WhatsApp Messenger was used for training and implementation support. Key community stakeholders met to discuss project progress and recommendations to improve adolescent mothers' health.
Study NCT04307056 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: The surgical approach can be open or laparoscopic. The procedure begins with lymph node dissection for the intermediate risk groups (PSA > 10 ng/mL and/or presence of grade 4 Gleason score). Total prostatectomy includes removal of the seminal vesicles. It can preserve 1 or 2 neurovascular bundles, depending on the cancer stage and/or the choice expressed by the patient. The vesicourethral suture is either a running or interrupted suture, and there is drainage by a bladder catheter for at least 5 days.
Study NCT04307056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound (HIFU) Treatment
Description: The treatment with High Intensity Focused Ultrasound (HIFU) evaluated in this study will be delivered by 2 types of medical devices currently available on the market, Ablatherm® and Focal One®. They are both computer-controlled and provided with an endo-rectal probe with integrated ultrasound, enabling planning and the monitoring of treatment of localized prostate cancer in realtime.
Study NCT02315014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whey protein
Description: whey protein.
Study NCT02315014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo.
Study NCT02443909 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: endoscopic stone treatment with flexible ureteroscopy and 20w holmium laser device
Study NCT02443909 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power)
Study NCT00995774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional functional training
Description: 12 sessions of conventional therapy for the arm and hand from a physical therapist
Study NCT03069326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.
Study NCT03069326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.
Study NCT04131348 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: botulinum toxin type A
Description: From to December 2016 to December 2018, a single-center prospective comparative study was performed in 80 patients with LMIH at our tertiary center.
Study NCT03899389 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: plasma samples collection
Description: Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples
Study NCT01250782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: 0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
Study NCT01250782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum
Description: 100 mL of physiological serum indistinguishable from active comparator
Study NCT02374944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hardware removal
Description: Comparison of implant retention vs. scheduled implant removal in skeletally mature patients with previously operatively treated Lisfranc injuries requiring screw and/or plate fixation.
Study NCT00366444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium (XP21L)
Description: 25 mg every 6 hours
Study NCT00366444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every 6 hours